Table 2.
Univariate and multivariate Cox hazard model for progression-free survival and overall survival of RAM + DOC.
| Items | Progression-free survival | Overall survival | ||
|---|---|---|---|---|
| (comparator) | Univariate | Multivariate | Univariate | Multivariate |
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |
| P-value | P-value | P-value | P-value | |
| VEGF-A high | 0.68 (0.34-1.37) | 1.57 (0.59-4.16) | ||
| (vs. VEGF-A low) | P = .28 | P = .36 | ||
| VEGF-D high | 2.17 (1.02-4.62) | 2.64 (1.15-6.03) | 4.94 (1.60-15.3) | 7.25 (1.95-26.9) |
| (vs. VEGF-D low) | P = .04 | P = .02 | P = .005 | P = .003 |
| sPD-L1 high | 1.72 (0.84-3.50) | 1.83 (0.71-4.77) | ||
| (vs. sPD-L1 low) | P = .14 | P = .21 | ||
| Age ≥ 75 | 0.34 (0.05-2.51) | 0.21 (0.03-1.63) | 5.03 (0.99–25.3) | 4.69 (0.88-24.8) |
| (vs. < 75) | P = .29 | P = .14 | P = .05 | P = .07 |
| Male sex | 1.37 (0.62-3.01) | 1.53 (0.64-3.70) | 1.10 (0.40-3.06) | 0.50 (0.15-1.63) |
| (vs. female sex) | P = .43 | P = .34 | P = .85 | P = .25 |
| ECOG-PS 2 | 1.38 (0.32-5.89) | 2.50 (0.49-12.8) | 1.58 (0.32-7.90) | 2.61 (0.41-16.7) |
| (vs. 0,1) | P = .66 | P = .27 | P = .58 | P = .31 |
| Smoker | 1.01 (0.41-2.48) | 0.62 (0.20-1.92) | ||
| (vs. never smoker) | P = .99 | P = .41 | ||
| Adeno | 0.72 (0.30-1.73) | 1.10 (0.31-3.84) | ||
| vs. non-Adeno | P = .47 | P = .88 | ||
| PD-L1 ≥ 50% | 0.54 (0.19-1.56) | 0.31 (0.04-2.32) | ||
| (vs. < 50%) | P = .26 | P = .25 | ||
| EGFR mutation positive | 1.56 (0.59-4.12) | 0.86 (0.20-3.75) | ||
| (vs. all others) | P = .37 | P = .83 | ||
| Liver metastasis | 2.77 (0.63-12.2) | 2.78 (0.33-23.1) | ||
| (vs. non liver metastasis) | P = .18 | P = .34 | ||
| Brain metastasis | 1.09 (0.50-2.37) | 1.01 (0.32-3.13) | ||
| (vs. non brain metastasis) | P = .84 | P = .99 | ||
| Bone metastasis | 1.50 (0.73-3.01) | 1.02 (0.38-2.77) | ||
| (vs. non bone metastasis) | P = .37 | P = .96 | ||
| Bevacizumab administration | 1.49 (0.64-3.48) | 1.24 (0.40-3.80) | ||
| (vs. non Bevacizumab administration) | P = .36 | P = .71 | ||
| Interval from combined chemoimmunotherapy to RAM + DOC ≥ 60 days | 1.98 (0.83-4.69) | 0.73 (0.21-2.56) | ||
| (vs. < 60 days) | P = .12 | P = .62 | ||
| PFS of combined chemoimmunotherapy > 8.8 months | 0.58 (0.28–1.17) | 0.59 (0.23-1.53) | ||
| (vs. < 8.8 months) | P = .13 | P = .28 | ||
| discontinuation of combined chemoimmunotherapy due to progression disease | 1.14 (0.40-3.29) | 2.70 (0.36-20.5) | ||
| (vs. due to adverse event) | P = .80 | P = .34 | ||